In research insights of the last few years, immune checkpoint inhibitors (ICIs), represented by programmed cell death receptor-1 (PD-1)/programmed death receptor ligand-1 (PD-L1) inhibitors, have attracted increasing attention due to durable clinical benefit along w1ith low toxicity in patients with NSCLC (16). This evidence concerns the gene CD274 and non-small cell lung carcinoma.